Francesca Gilli, MS, PhD
Assistant Professor of Neurology
2000 MS (Medical Biotechnology), Università degli Studi di Torino (Italy)
2005 PhD (Human Biology), Università degli Studi di Torino (Italy)
2008-2011 Clinical Chemistry and Laboratory Medicine Fellowship, Università degli Studi di Torino (Italy)
DHMC, HB 7999
1 Medical Center Drive
Lebanon NH 03756
Phone: (603) 650-5433 (Lab)
Dr. Gilli’s principal research interest is understanding the cellular and molecular pathways that contribute to neuroinflammation and central nervous system (CNS)-related tissue damage in Multiple Sclerosis (MS). The goal of Dr. Gilli’s current research is to elucidate how inflammation contributes to neurodegeneration and disability progression. The overall intention of this work is to identify new therapeutic targets or strategies that will improve our ability to manage progressive MS as well as other neurodegenerative diseases.
Genzyme-Sanofi: 2019-2020 -(PI) Antiviral effects of Teriflunomide.
Italian MS Society 2018/R/6: 2019-2020 -(PI) Sex effects on intrathecal humoral inflammation and disease progression in multiple sclerosis.
Hitchcock Foundation Scholar Award: 2017-2019 – (PI) lntrathecal B-cell response pattern for improved diagnosis and management of progressive Multiple Sclerosis.
Hitchcock Foundation Pilot Award: 2016-2017 – (PI) Plasmalemma vesicle associated protein (PV1) as a novel target in neuroinflammation.
Biogen Idec Research Grant: 2014-2016 – (PI) Interaction of PEG-IFNβ with Antibodies to Native IFNβ
Hitchcock Foundation Pilot Award: 2014-2015 – (PI) Toward reliable biomarkers in MS: Microarray analysis of spinal cord gene expression in animal models of Multiple Sclerosis.
Lecturer - Scientific basis of diseases 1 (PEMM 101)
Lecturer - Ethical and Responsible Conduct of Research (PEMM 124)
Lecturer - Neurobiology of Diseases (PEMM 211)
Lecturer - Neuroscience II -Neuroimmunology module (PEMM 212)
Lecturer - Advanced Biomedical Sciences (PEMM 271)
Born in Italy, Dr. Gilli earned a M.S. in Medical Biotechnology and a Ph.D. in Human Biology from the Università degli Studi di Torino (Italy). She then completed her postdoctoral research in neuroimmunology at Università degli Studi di Torino (Italy), and University of Basel (Switzerland). Her postdoctoral research focused on the immunogenicity and biological action of IFNβ therapy in patients with MS, and, later, on the molecular mechanisms behind the adaptive immune response in pregnancy in MS. She also completed a Clinical Chemistry and Laboratory Medicine Fellowship at the Università degli Studi di Torino (Italy) in 2011. In 2014, Dr. Gilli joined the faculty in the Neurology Department of the Geisel School of Medicine as an Assistant Professor, where she works as a basic scientist affiliated with the Multiple Sclerosis Center at Dartmouth.
Editorial: B Cells in Inflammatory and Neurodegenerative Diseases of the Central Nervous System.
Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.
Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on "Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function".
Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis.
SeXX Matters in Multiple Sclerosis.
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells.
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice.
Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.
Differential neuro-immune patterns in two clinically relevant murine models of multiple sclerosis.
Clinical utility of a molecular signature in inflammatory demyelinating disease.